ERBB2 and breast carcinoma: (vi) Immunotherapy appears to be promising for treatment of breast cancer, especially for the case of triple negative breast cancer (TNBC) tumors [tumors negative for ER, progesterone receptor (PR) and HER2] (24, 25).